2010 was a strong financial year for Safeguard, with two significant partner company deals. First, Eli Lilly and Company (NYSE: LLY) acquired outstanding shares of Avid Radiopharmaceuticals for an upfront payment of $300 million, representing an initial cash-on-cash return of 3x for Safeguard Scientifics, which could increase to 8x based upon achievement of aggressive revenue milestones.

Over its three-year partnership with Avid Radiopharmaceuticals, Safeguard played an active role in the company’s growth and maturation as it sought approval for its game-changing imaging agents to enable early detection of pathology associated with neurodegenerative diseases.

(Visited 341 times, 1 visits today)